NCT02478502View on ClinicalTrials.gov

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Testicular Cancer
Interventions
DRUG

cabazitaxel

cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy

Trial Locations (4)

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T), Meldola

75185

University Hospital of Uppsala, Department of Oncology, Uppsala

Unknown

Rigshospitalet, Copenhagen

N-0424

Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University Hospital, Akershus

OTHER